Several clinical trials have evaluated the addition of immunotherapy to standard chemotherapy in the frontline treatment of patients with advanced non–small cell lung cancer, all of which echo similar conclusions: these combinations are a mainstay in this population.
The development of cancer treatments and diagnostic tools using CRISPR/Cas9 and other gene-editing technology is a promising area of research in the United States, although the field is moving into human studies at a relatively slow pace.
The FDA has accepted a supplemental biologics license application for atezolizumab, carboplatin, and nab-paclitaxel as a first-line treatment for patients with metastatic nonsquamous non–small cell lung cancer.
Petros Grivas, MD, PhD, discusses the rapidly evolving field of locally advanced and metastatic bladder cancer.
The European Commission has approved nivolumab combined with low-dose ipilimumab as a frontline treatment for patients with intermediate- and poor-risk advanced renal cell carcinoma.
Sumanta K. Pal, highlights the different combination regimens that are making headlines in the treatment of patients with metastatic renal cell carcinoma.
Advancing cancer care requires more than just science. It’s a collective effort driven by passionate individuals and organizations dedicated to making a difference for those living with and affected by cancer.
Immune checkpoint inhibitors, with their favorable safety and antitumor activity profiles, have heralded a new era in urothelial carcinoma treatment.
Kwok-Kin Wong, MD, PhD, discusses updates in non–small cell lung cancer and the importance of enrolling patients in clinical trials to further progress the field.
Joaquim Bellmunt, MD, PhD, provides insight on how to navigate the complex treatment paradigm of metastatic bladder cancer.